Results 71 to 80 of about 20,576 (195)

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, Volume 4, Issue 1, March 2026.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience

Journal of the Scientific Society, 2016
Introduction: Aflibercept in combination with FOLFIRI has been shown to improve overall survival in the pivotal VELOUR study. Aflibercept has not yet been marketed in India.
Govind Babu, Umesh Das, Kuntejowdahalli Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu   +5 more
doaj   +1 more source

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer [PDF]

, 2017
Rationale: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%.
Archibugi, Livia, Botticelli, Andrea, Castaldi, Nadia, Falcone, Rosa, Marchetti, Paolo, Mazzuca, Federica, Osti, Mattia Falchetto, Roberto, Michela   +7 more
core   +1 more source

Renal‐Limited Thrombotic Microangiopathy due to Anti‐VEGF/TKI Immunotherapy for Metastatic Renal Cell Carcinoma Presenting as Nephrotic Syndrome: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Vascular endothelial growth factor (VEGF) inhibition may result in proteinuria, worsening hypertension, chronic kidney injury, or glomerular disease. Recently, systemic VEGF inhibition has been reported to cause nephrotic disorders and thrombotic microangiopathy (TMA).
Sundus Sardar, Ahmad Matarneh, Omar K. Salameh, Abdel‐Rauof M. Akkari, Monika Joshi, Erik Washburn, Nasrollah Ghahramani, Naman Trivedi   +7 more
wiley   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, EarlyView.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Secretory autophagy and epithelial‐to‐mesenchymal transition in cadaveric AMD samples: Novel pathways in disease progression

Acta Ophthalmologica, Volume 104, Issue 2, Page 239-251, March 2026.
Abstract Purpose To examine the presence of secretory autophagy and epithelial–mesenchymal transition (EMT) in the macular retinal pigment epithelium (RPE) of human cadaver eyes with different forms of age‐related macular degeneration (AMD). Methods Human cadaver macula samples representing dry and wet AMD, as well as age‐matched controls, were ...
Iswariyaraja Sridevi Gurubaran, Ali Koskela, Hanna Heloterä, Kai Kaarniranta   +3 more
wiley   +1 more source

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Molecular Therapy: Methods & Clinical Development
Ixoberogene soroparvovec (ixo-vec), formerly ADVM-022, is an adeno-associated virus (AAV) gene therapy using the AAV.7m8 capsid for intravitreal delivery (IVT) to transduce retinal tissue and produce sustained intraocular aflibercept for treating ...
Kris Poulsen, Kelly Hanna, Julio Nieves, Ngoc Nguyen, Pallavi Sharma, Ruslan Grishanin, Romu Corbau, Szilárd Kiss   +7 more
doaj   +1 more source

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks

Indian Journal of Ophthalmology, 2015
In this study, we reported the clinical results of switching from ranibizumab to aflibercept for the treatment of an insufficient responder with choroidal neovascularization (CNV) secondary to angioid streaks (AS).
Ebru Esen, Selçuk Sizmaz, Nihal Demircan   +2 more
doaj   +1 more source

Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions [PDF]

, 2014
Tumours require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands.
A Carrato, A Gramont de, A Grothey, A Grothey, A Hauschild, A McIntyre, A Rapisarda, A Sandler, AA Veldt Van der, AA Veldt van der, AD Norden, AD Smith, AD Smith, AK Olsson, AM Brufsky, AM Jubb, Andrew R. Reynolds, AR Reynolds, AS Bailey, AS Chung, AS Chung, AW Griffioen, B Dome, B Dome, B Escudier, B Escudier, B Nico, B Nordlinger, B Oosthuyse, B Sennino, B Sitohy, BI Rini, BI Rini, BI Rini, BI Rini, BJ Giantonio, C Aghajanian, C Anderberg, C Bais, C Fischer, C Fischer, C Porta, C Raimondi, C Schuster, C Stockmann, CH Barrios, CJ Allegra, CJ Allegra, CN Sternberg, CN Sternberg, D Cunningham, D Grunhagen, D Huang, D Lambrechts, D Lyden, D Maru, D Miles, D Ribatti, DI Gabrilovich, DW McMillin, DW Miles, DW Miles, E Cutsem Van, E Cutsem Van, E Cutsem Van, E Cutsem Van, E Guerin, E Langenkamp, E Raymond, E Tomaso di, E Tomaso di, EA Kuczynski, F Collinson, F Fan, F Fan, F Loupakis, F Pezzella, F Pezzella, F Pezzella, F Shojaei, F Shojaei, F Shojaei, F Shojaei, F Shojaei, F Stessels, F Winkler, F Winkler, F Zhang, G Bergers, G Bergers, G Lorenzo Di, G Minckwitz von, G Nardo, GC Jayson, GG Eynden Van den, GG Eynden Van den, H Hashizume, H Hurwitz, HD Bear, HJ Hammers, HL Kindler, HS Rugo, HT Tran, HX Chen, I Helfrich, IF Tannock, IM Desar, IN Zama, J Bennouna, J Bergh, J Folkman, J Lu, J Rak, J Xu, JA Joyce, JC Soria, JC Welti, JC Welti, JF Groot de, JI Greenberg, JL Li, JL Rubenstein, JL Yu, JL Yu, JM Butler, JM Ebos, JM Ebos, JM Ebos, JM Ebos, JM Llovet, JM Llovet, JP Crown, JP Dales, JR Hecht, JR Rossari, JS Wey, K Miller, KB Blagoev, KB Kim, KD Miller, KJ Luzzi, KM Hodivala-Dilke, KP Olive, KS Han, KT Flaherty, KT Flaherty, KV Lu, L Cheng, L Gianni, L Ricci-Vitiani, L Yang, L Zhang, LA Gilbert, LB Saltz, LM Coussens, LM Ellis, LM Ellis, LS Fournier, M Paez-Ribes, M Palma De, M Palma De, M Reck, M Reck, M Singh, MJ Bissell, MP Barr, MR Mancuso, Naveen S. Vasudev, NC Turner, NJ Robert, NJ Robert, NS Vasudev, O Casanovas, O Keunen, O Straume, OM Hahn, P Carmeliet, P Carmeliet, P Carmeliet, P Guo, P Osterlund, P Sardari Nia, P Wolter, PB Vermeulen, PD Nathan, PJ Johnson, PS Hegde, Q Pan, R Dienstmann, R Erber, R Folberg, R Hlushchuk, R Kalluri, R Leite de Oliveira, R Porschen, R Wang, R Wong, RA Burger, RJ Motzer, RJ Motzer, RJ Motzer, RK Jain, RK Jain, RK Jain, RM Shaheen, RS Kerbel, RS Kerbel, RT Tong, S Koch, S Kopetz, S Lee, S Loges, S Tugues, S Veire Van de, SA Yousem, SB Kaye, SB Wedam, SR Alberts, T Andre, T Cascone, T Donnem, T Gruenberger, T Jiang, T Powles, TA Yap, TC Tang, TE Hutson, TJ Perren, V Moreno Garcia, VG Cooke, WA Spannuth, WK Kelly, WK Rathmell, WP Leenders, WS Carbonell, WS Kamoun, WW Kilarski, X Li, X Xian, XD Zhu, Y Crawford, Y Shaked, Y Shaked, YL Hu, YS Chun   +244 more
core   +2 more sources

Interventions for submacular haemorrhage: A systematic review and network meta‐analysis of controversies—On behalf of the Spanish Vitreo‐Retinal Society (SERV)

Acta Ophthalmologica, Volume 104, Issue 2, Page 139-163, March 2026.
Abstract Purpose This systematic review aims to evaluate and synthesize the existing literature on the interventions used for submacular haemorrhage (SMH), highlighting the controversies and differences in clinical practice. Method A systematic review was conducted following the PRISMA guidelines.
Salvador Pastor‐Idoate, Pablo Redruello‐Guerrero, Laura de Juan Hernández, Gregorio Benites‐Narcizo, Mario Rivera‐Izquierdo, José García‐Arumí, José Carlos Pastor Jimeno   +6 more
wiley   +1 more source